Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN5A | Q14524 | 1/20 | 0.43 |
| ▸ | TGFBR1 | P36897 | 17/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4898307 | 0.84 | TGFBR1 (0.34) | TGFBR1 | |
| SCHEMBL4896435 | 0.84 | TGFBR1 (0.46) | TGFBR1DYRK1AMAPK14 | |
| SCHEMBL5138589 | 0.83 | TGFBR1 (0.47) | SCN5ATGFBR1MAPK14 | |
| SCHEMBL4160099 | 0.78 | TGFBR1 (0.49) | SCN5ATGFBR1DYRK1AMAPK14 | |
| SCHEMBL4011848 | 0.77 | TGFBR1 (0.55) | TGFBR1MAPK14 | |
| SCHEMBL5138651 | 0.77 | TGFBR1 (0.67) | TGFBR1MAPK14 | |
| SCHEMBL5138253 | 0.74 | TGFBR1 (0.48) | TGFBR1MAPK14 | |
| SCHEMBL4902499 | 0.74 | TGFBR1 (0.46) | TGFBR1MAPK14HDAC1HDAC6 | |
| SCHEMBL4904075 | 0.72 | NPC1 (0.43) | TGFBR1DYRK1A | |
| SCHEMBL4894431 | 0.71 | KDM4E (0.44) | DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080171755-A1 | Pyrimidinylpyrazoles as Tgf-Beta Inhibitors | LEE WEN-CHERNG | 2008-07-17 | — | — | US | claimed |
| EP-1804801-A2 | METHODS OF TREATING VASCULAR INJURIES | Biogen Idec MA, Inc. (US) | 2007-07-11 | — | — | EP | claimed |
| EP-1786803-A1 | PYRIMIDINYLPYRAZOLES AS TGF-BETA INHIBITORS | Biogen Idec MA, Inc. (US) | 2007-05-23 | — | — | EP | claimed |
| WO-2006044509-A2 | METHODS OF TREATING VASCULAR INJURIES | BIOGEN IDEC MA INC. (US) | 2006-04-27 | — | — | WO | claimed |
| WO-2006026305-A1 | PYRIMIDINYLPYRAZOLES AS TGF-BETA INHIBITORS | BIOGEN IDEC MA INC (US) | 2006-03-09 | — | — | WO | claimed |
| US-20080171755-A1 | Pyrimidinylpyrazoles as Tgf-Beta Inhibitors | LEE WEN-CHERNG | 2008-07-17 | — | — | US | disclosed |
| WO-2008013928-A2 | TREATMENT OF CANCER WITH INTERFERON GENE DELIVERY IN COMBINATION WITH A TGF-BETA INHIBITOR | BIOGEN IDEC MA INC. (US) | 2008-01-31 | — | — | WO | disclosed |
| EP-1786803-A1 | PYRIMIDINYLPYRAZOLES AS TGF-BETA INHIBITORS | Biogen Idec MA, Inc. (US) | 2007-05-23 | — | — | EP | disclosed |
| WO-2006026305-A1 | PYRIMIDINYLPYRAZOLES AS TGF-BETA INHIBITORS | BIOGEN IDEC MA INC (US) | 2006-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171755-A1 | Pyrimidinylpyrazoles as Tgf-Beta Inhibitors | TGFBR1, SMAD3, ALK | SCN5A 678/4885TGFBR1 1/4885DYRK1A 3927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.